Base de dados : MEDLINE
Pesquisa : D27.505.954.796.250 [Categoria DeCS]
Referências encontradas : 2246 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 225 ir para página                         

  1 / 2246 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29338445
[Au] Autor:Antoniu SA
[Ad] Endereço:a Department of Medicine II-Nursing/Palliative Care , University of Medicine and Pharmacy Grigore T Popa Iasi , Iasi , Romania.
[Ti] Título:Investigational inhaled therapies for non-CF bronchiectasis.
[So] Source:Expert Opin Investig Drugs;27(2):139-146, 2018 Feb.
[Is] ISSN:1744-7658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Bronchiectasis not related to cystic fibrosis (non-CF bronchiectasis) are associated with a high unmet therapeutic need due to the lack of specifically authorized medications, especially via the inhalation route. In non-CF bronchiectasis chronic infection with Pseudomonas aeruginosa is common and favored by the persistent local inflammation and viscid sputum production. Therefore inhaled antibiotics, mucolytics or anti-inflammatory agents could represent appropriate therapeutic interventions in this setting Areas covered: This review herein discusses the inhaled therapies currently under investigation for non-CF bronchiectasis and their potential therapeutic positioning in exacerbation versus stable state. Expert opinion: Inhaled antipseudomonal antibiotics are of promising efficacy, but further efforts should also be made to detect bactericidal approaches against Burkholderia cepacia complex, and to interfere chronic inflammation topically.
[Mh] Termos MeSH primário: Bronquiectasia/tratamento farmacológico
Desenho de Drogas
Drogas em Investigação/uso terapêutico
[Mh] Termos MeSH secundário: Administração por Inalação
Animais
Antibacterianos/administração & dosagem
Antibacterianos/uso terapêutico
Anti-Inflamatórios/administração & dosagem
Anti-Inflamatórios/uso terapêutico
Bronquiectasia/etiologia
Bronquiectasia/microbiologia
Doença Crônica
Drogas em Investigação/administração & dosagem
Drogas em Investigação/farmacologia
Expectorantes/administração & dosagem
Expectorantes/uso terapêutico
Seres Humanos
Infecções por Pseudomonas/tratamento farmacológico
Pseudomonas aeruginosa
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents); 0 (Drugs, Investigational); 0 (Expectorants)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2018.1427728


  2 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320622
[Au] Autor:Tausan D; Ristic A; Zvezdin B
[Ti] Título:Kartagener's syndrome: A case report.
[So] Source:Vojnosanit Pregl;73(9):873-6, 2016 Sep.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Kartagener's syndrome is a recessive autosomal disease which is mainly seen to affect ciliary movement. The symptoms of the syndrome are the consequence of the defective motility of the cilia found in the respiratory tract and that results with recurrent lung infections caused by mucus stasis in the bronchi. Case report: A 37-year-old married, male father of one child, presented with a history of productive cough, wheezing, dispnea, headache, temporary fever. In his 9th year of age, 1986, situs inversus, sinusitis and pectus excavatum were diagnosed. In 1994 he was operated for correction of pectus excavatum. Bronchial asthma was diagnosed in 2008 when he was 31. In the last 2 years he had episodes of breathlessness, wheezing, cough, expectoration, headache, fever and fast declining lung function. The patient was treated with combination of inhaled bronchodilatators (inhaled corticosteroids + long-acting ß-2 agonist), and occasional administration of antibiotics, oral prednisolone, mucolytics in episodes of exacerbations of disease over a period of 7−14 days. Conclusion: Treatment for patients with this syndrome has not been established yet, but it is important to control chronic lung infections and prevent declining of lung function.
[Mh] Termos MeSH primário: Síndrome de Kartagener
Pulmão
[Mh] Termos MeSH secundário: Administração por Inalação
Adulto
Antibacterianos/administração & dosagem
Broncodilatadores/administração & dosagem
Progressão da Doença
Expectorantes/administração & dosagem
Glucocorticoides/administração & dosagem
Seres Humanos
Síndrome de Kartagener/complicações
Síndrome de Kartagener/diagnóstico por imagem
Síndrome de Kartagener/tratamento farmacológico
Síndrome de Kartagener/fisiopatologia
Pulmão/diagnóstico por imagem
Pulmão/efeitos dos fármacos
Pulmão/fisiopatologia
Masculino
Fatores de Tempo
Tomografia Computadorizada por Raios X
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bronchodilator Agents); 0 (Expectorants); 0 (Glucocorticoids)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.2298/VSP141020072T


  3 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29224994
[Au] Autor:Kuang Y; Li B; Fan J; Qiao X; Ye M
[Ad] Endereço:State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China.
[Ti] Título:Antitussive and expectorant activities of licorice and its major compounds.
[So] Source:Bioorg Med Chem;26(1):278-284, 2018 01 01.
[Is] ISSN:1464-3391
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Licorice has been used as an antitussive and expectorant herbal medicine for a long history. This work evaluated the activities of 14 major compounds and crude extracts of licorice, using the classical ammonia-induced cough model and phenol red secretion model in mice. Liquiritin apioside (1), liquiritin (2), and liquiritigenin (3) at 50 mg/kg (i.g.) could significantly decrease cough frequency by 30-78% (p < .01). The antitussive effects could be partially antagonized by the pretreatment of methysergide or glibenclamide, but not naloxone. Moreover, compounds 1-3 showed potent expectorant activities after 3 days treatment (p < .05). The water and ethanol extracts of licorice, which contain abundant 1 and 2, could decrease cough frequency at 200 mg/kg by 25-59% (p < .05), and enhance the phenol red secretion (p < .05), while the ethyl acetate extract showed little effect. These results indicate liquiritin apioside and liquiritin are the major antitussive and expectorant compounds of licorice. Their antitussive effects depend on both peripheral and central mechanisms.
[Mh] Termos MeSH primário: Antitussígenos/farmacologia
Tosse/tratamento farmacológico
Expectorantes/farmacologia
Glycyrrhiza/química
Fenolsulfonaftaleína/metabolismo
Extratos Vegetais/farmacologia
[Mh] Termos MeSH secundário: Administração Oral
Amônia
Animais
Antitussígenos/antagonistas & inibidores
Antitussígenos/química
Tosse/induzido quimicamente
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Expectorantes/química
Expectorantes/isolamento & purificação
Glibureto/farmacologia
Masculino
Metisergida/farmacologia
Camundongos
Camundongos Endogâmicos ICR
Estrutura Molecular
Extratos Vegetais/química
Extratos Vegetais/isolamento & purificação
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antitussive Agents); 0 (Expectorants); 0 (Plant Extracts); 7664-41-7 (Ammonia); I6G9Y0J1OJ (Phenolsulfonphthalein); SX6K58TVWC (Glyburide); XZA9HY6Z98 (Methysergide)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180106
[Lr] Data última revisão:
180106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE


  4 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28631682
[Au] Autor:Stepanova YE; Gotovyakhina TV; Korneenkov AA; Koren' EE
[Ad] Endereço:Saint-Petersburg Research Institute of Ear, Throat, Nose and Speech, Saint-Petersburg, Russia, 190013.
[Ti] Título:[The combined treatment of dysphonia in the subjects engaged in the voice and speech professions].
[Ti] Título:Kompleksnoe lechenie disfonii u lits golosorechevykh professii..
[So] Source:Vestn Otorinolaringol;82(3):48-53, 2017.
[Is] ISSN:0042-4668
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The objective of the present study was to evaluate the effectiveness of the application of homeovox for the combined treatment of small vocal cord nodules and acute laryngitis in the professional voice users. A total of 40 subjects presenting with dysphonia were examined after they were divided into two study groups and two groups of comparison depending on the nosological form of the pathological condition. The subjects comprising the study groups were given traditional therapy in the combination with the intake of homeovox whereas the patients included in the two groups of comparison received the traditional treatment alone. The outcome of the treatment was evaluated on days 1, 5, and 10 after the initiation of therapy based on the analysis of the changes in the videoendostroboscopic picture of the larynx and the acoustic characteristics obtained by the computer-assisted analysis of the voice. The analysis of the results of the combined treatment has demonstrated the statistically significant differences in some acoustic parameters of the voice between the subjects with small vocal cord nodules and acute laryngitis belonging to the study groups and the groups of comparison. It is concluded that the introduction of homeovox in the combined treatment of the patients presenting with the small nodules in the vocal cords and acute catarrhal laryngitis accelerates the recovery of the acoustic characteristics of the voice within various periods after the onset of the treatment in comparison with the patients treated with the use of traditional therapy alone.
[Mh] Termos MeSH primário: Disfonia
Materia Medica/administração & dosagem
Doenças Profissionais
Qualidade da Voz/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Anti-Inflamatórios/administração & dosagem
Monitoramento de Medicamentos
Quimioterapia Combinada/métodos
Disfonia/diagnóstico
Disfonia/tratamento farmacológico
Disfonia/etiologia
Disfonia/fisiopatologia
Expectorantes/administração & dosagem
Feminino
Seres Humanos
Laringoscopia/métodos
Masculino
Meia-Idade
Doenças Profissionais/diagnóstico
Doenças Profissionais/tratamento farmacológico
Doenças Profissionais/etiologia
Doenças Profissionais/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Expectorants); 0 (Materia Medica)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.17116/otorino201782348-53


  5 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28631673
[Au] Autor:Safronenko LA; Davydova AP; Karpov VV; Lukashevich MG; Novikov VA
[Ad] Endereço:Rostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia, 344000.
[Ti] Título:[The problems associated with the treatment of stenosing laryngotracheitis in the children (the results of the 35 year-long experience)].
[Ti] Título:Problemy lecheniia stenoziruiushchego laringotrakheita u detei (rezul'taty 35-letnego opyta)..
[So] Source:Vestn Otorinolaringol;82(3):19-21, 2017.
[Is] ISSN:0042-4668
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Stenosing laryngotracheitis (SLT) affecting the children is considered to be an emergency pediatric condition associated with ENT pathology. Its treatment presents a serious challenge for otolaryngologists, pediatricians, specialists in communicable diseases, allergologists, etc. We have undertaken a retrospective analysis of the available data with a view to summarizing the tendencies in the evolution of SLT morbidity. The results of the 35 year-long experience with the use of the currently available therapeutic strategies for the treatment of the children suffering from stenosing laryngotracheitis are presented. Special emphasis is laid on the advantages of the combined treatment of the patients presenting with this condition based at a specialized infectious department with the participation of an otorhinolaryngologist.
[Mh] Termos MeSH primário: Sistemas de Liberação de Medicamentos
Laringite
Laringoestenose
Administração dos Cuidados ao Paciente
Traqueíte
[Mh] Termos MeSH secundário: Administração por Inalação
Anti-Infecciosos/uso terapêutico
Criança
Terapia Combinada/métodos
Terapia Combinada/tendências
Sistemas de Liberação de Medicamentos/métodos
Sistemas de Liberação de Medicamentos/tendências
Expectorantes/uso terapêutico
Feminino
Hospitalização/estatística & dados numéricos
Seres Humanos
Imunidade/efeitos dos fármacos
Fatores Imunológicos/farmacologia
Laringite/complicações
Laringite/imunologia
Laringoestenose/epidemiologia
Laringoestenose/etiologia
Laringoestenose/fisiopatologia
Laringoestenose/terapia
Masculino
Nebulizadores e Vaporizadores
Administração dos Cuidados ao Paciente/métodos
Administração dos Cuidados ao Paciente/tendências
Estudos Retrospectivos
Fatores de Risco
Federação Russa/epidemiologia
Traqueíte/complicações
Traqueíte/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Expectorants); 0 (Immunologic Factors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.17116/otorino201782319-21


  6 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28601320
[Au] Autor:Erdem A; Gedikli E; Yersal N; Karaismailoglu S; Muftuoglu S; Fadillioglu E; Tuncer M
[Ad] Endereço:Department of Physiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Electronic address: aerdem@hacettepe.edu.tr.
[Ti] Título:Protective role of erdosteine pretreatment on oleic acid-induced acute lung injury.
[So] Source:J Surg Res;213:234-242, 2017 Jun 01.
[Is] ISSN:1095-8673
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Erdosteine is a mucolytic agent with antioxidant and anti-inflammatory effects. We evaluated the protective effect of erdosteine pretreatment on oleic acid (OA)-induced acute lung injury. MATERIALS AND METHODS: Twenty-four male Wistar Albino rats were assigned to four treatments: control (oral saline + 50 µL intravenous [i.v.] saline), OA (oral saline + 50 µL i.v. OA), erdosteine (150 mg/kg oral erdosteine + 50 µL i.v. saline), and OA + erdosteine (150 mg/kg oral erdosteine + 50 µL i.v. OA). Four hours after OA injection, lung tissues were excised for biochemical and histopathologic evaluation. RESULTS: OA treatment increased lung weight and tissue malondialdehyde and protein carbonyl levels, but erdosteine pretreatment significantly suppressed these changes (0.57 ± 0.1 g, 3.27 ± 0.48 nmol/mg protein, and 33.57 ± 4.6 nmol/mg protein, respectively, for OA versus 0.36 ± 0.02 g, 1.84 ± 0.15 nmol/mg protein, and 22.10 ± 2.55 nmol/mg protein, respectively, for OA + erdosteine; P < 0.05 for all). Erdosteine pretreatment increased the activities of the antioxidant enzymes, catalase, and glutathione peroxidase (0.16 ± 0.03 k/g and 0.3 ± 0.01 U/mg protein, respectively, for OA versus 0.33 ± 0.05 k/g and 0.34 ± 0.01 U/mg protein, respectively, for OA + erdosteine; P < 0.05 for both). Erdosteine pretreatment also significantly decreased the median numbers of intra-alveolar macrophages and intra-alveolar and interstitial neutrophils (29.0, 17.0, and 15.0, respectively, for OA versus 12.5, 4.0, and 6.5, respectively, for OA + erdosteine; P < 0.001 for all). CONCLUSIONS: Erdosteine pretreatment increased the activities of antioxidant enzymes and decreased macrophage and neutrophil accumulation, thereby ameliorating the inflammatory effects of OA treatment. Erdosteine pretreatment prevents OA-induced oxidative stress and inflammation and protects the lung tissue against acute lung injury.
[Mh] Termos MeSH primário: Lesão Pulmonar Aguda/prevenção & controle
Expectorantes/uso terapêutico
Ácido Oleico/efeitos adversos
Substâncias Protetoras/uso terapêutico
Tioglicolatos/uso terapêutico
Tiofenos/uso terapêutico
[Mh] Termos MeSH secundário: Lesão Pulmonar Aguda/induzido quimicamente
Lesão Pulmonar Aguda/imunologia
Lesão Pulmonar Aguda/metabolismo
Administração Oral
Animais
Antioxidantes/metabolismo
Biomarcadores/metabolismo
Esquema de Medicação
Macrófagos Alveolares/metabolismo
Masculino
Neutrófilos/metabolismo
Distribuição Aleatória
Ratos
Ratos Wistar
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Biomarkers); 0 (Expectorants); 0 (Protective Agents); 0 (Thioglycolates); 0 (Thiophenes); 2UMI9U37CP (Oleic Acid); 76J0853EKA (erdosteine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170612
[St] Status:MEDLINE


  7 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28420285
[Au] Autor:Akdag Cayli Y; Sahin S; Buttini F; Balducci AG; Montanari S; Vural I; Oner L
[Ad] Endereço:a Faculty of Pharmacy , Hacettepe University , Ankara , Turkey.
[Ti] Título:Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
[So] Source:Drug Dev Ind Pharm;43(8):1378-1389, 2017 Aug.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: This study aimed to design and characterize an inhalable dry powder of ciprofloxacin or levofloxacin combined with the mucolytics acetylcysteine and dornase alfa for the management of pulmonary infections in patients with cystic fibrosis. METHODS: Ball milling, homogenization in isopropyl alcohol and spray drying processes were used to prepare dry powders for inhalation. Physico-chemical characteristics of the dry powders were assessed via thermogravimetric analysis, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR), X-ray diffractometry and scanning electron microscopy. The particle size distribution, dissolution rate and permeability across Calu-3 cell monolayers were analyzed. The aerodynamic parameters of dry powders were determined using the Andersen cascade impactor (ACI). RESULTS: After the micronization process, the particle sizes of the raw materials significantly decreased. X-ray and DSC results indicated that although ciprofloxacin showed no changes in its crystal structure, the structure of levofloxacin became amorphous after the micronization process. FT-IR spectra exhibited the characteristic peaks for ciprofloxacin and levofloxacin in all formulations. The dissolution rates of micro-homogenized and spray-dried ciprofloxacin were higher than that of untreated ciprofloxacin. ACI results showed that all formulations had a mass median aerodynamic diameter less than 5 µm; however, levofloxacin microparticles showed higher respirability than ciprofloxacin powders did. The permeability of levofloxacin was higher than those of the ciprofloxacin formulations. CONCLUSION: Together, our study showed that these methods could suitably characterize antibiotic and mucolytic-containing dry powder inhalers.
[Mh] Termos MeSH primário: Ciprofloxacino/administração & dosagem
Ciprofloxacino/uso terapêutico
Fibrose Cística/tratamento farmacológico
Desoxirribonuclease I/química
Expectorantes/química
Levofloxacino/administração & dosagem
Levofloxacino/uso terapêutico
Pós/administração & dosagem
[Mh] Termos MeSH secundário: Administração por Inalação
Varredura Diferencial de Calorimetria
Química Farmacêutica
Ciprofloxacino/química
Fibrose Cística/fisiopatologia
Desoxirribonuclease I/administração & dosagem
Inaladores de Pó Seco
Expectorantes/farmacocinética
Seres Humanos
Levofloxacino/química
Microscopia Eletrônica de Varredura
Tamanho da Partícula
Pós/química
Proteínas Recombinantes/administração & dosagem
Proteínas Recombinantes/química
Espectroscopia de Infravermelho com Transformada de Fourier
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Expectorants); 0 (Powders); 0 (Recombinant Proteins); 5E8K9I0O4U (Ciprofloxacin); 6GNT3Y5LMF (Levofloxacin); EC 3.1.21.1 (Deoxyribonuclease I); EC 3.1.21.1 (dornase alfa)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170420
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1318902


  8 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28405161
[Au] Autor:Yan X; Song Y; Shen C; Xu W; Chen L; Zhang J; Liu H; Huang M; Lai G; Qian G; Wang J; Ye X; Zheng J; Bai C
[Ad] Endereço:Department of Pulmonary and Critical Care Medicine, Second Hospital Affiliated to Hebei Medical University, Hebei.
[Ti] Título:Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.
[So] Source:Int J Chron Obstruct Pulmon Dis;12:803-812, 2017.
[Is] ISSN:1178-2005
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Airway mucus hypersecretion is a frequent symptom associated with acute and chronic airway disease. Inhibition of mucus production or promotion of mucolysis not only relieved symptoms but also improved disease outcomes. There are numerous available mucoactive medicines for prescription, and how to select them properly for different diseases is important for clinical practice. So far, there is no one consensus or guideline reported. A group of Chinese pulmonary physicians worked together to complete this consensus based on literature review, summarized mechanism and usage of each classical mucoactive medicine. In general, antioxidant mucoactive medicines play an important role in chronic airway disease, including but not limited to airway mucus clearance, reduced acute exacerbation and improved pulmonary function.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Expectorantes/uso terapêutico
Pulmão/efeitos dos fármacos
Depuração Mucociliar/efeitos dos fármacos
Muco/secreção
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
Pneumologistas
[Mh] Termos MeSH secundário: Antioxidantes/efeitos adversos
China
Consenso
Progressão da Doença
Expectorantes/efeitos adversos
Seres Humanos
Pulmão/fisiopatologia
Pulmão/secreção
Doença Pulmonar Obstrutiva Crônica/diagnóstico
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
Qualidade de Vida
Recuperação de Função Fisiológica
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Nm] Nome de substância:
0 (Antioxidants); 0 (Expectorants)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.2147/COPD.S114423


  9 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28291433
[Au] Autor:Göçer H; Emir D; Önger ME; Dabak N
[Ad] Endereço:Department of Orthopedics and Traumatology, Medical Faculty of Ondokuz Mayis University, 55105 Atakum, Samsun, Turkey. drhasangocer@hotmail.com.
[Ti] Título:Effects of bone cement loaded with teicoplanin, N-acetylcysteine or their combination on Staphylococcus aureus biofilm formation: an in vitro study.
[So] Source:Eklem Hastalik Cerrahisi;28(1):13-8, 2017 Apr.
[Is] ISSN:1309-0313
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: This study aims to demonstrate the antibiofilm effects of teicoplanin alone, N-acetyl cysteine (NAC) alone, or combination of both compounds when mixed with bone cement. MATERIALS AND METHODS: A total of four groups were formed by using six cement samples in each, prepared with bone cement having different contents in each group. Group 1 (control group): cement alone without any drugs added. Group 2: 40 g cement, 400 mg teicoplanin. Group 3: 40 g cement, 6 g NAC. Group 4: 40 g cement, 6 g NAC, 400 mg teicoplanin. All cement samples were infected with Staphylococcus aureus for 48 hours at 36.5 °C. Bacterial colonies were then counted by serial dilution method. Bacteria were counted using scanning electron microscopic (SEM) images. RESULTS: Counts of bacteria colonies were 5.83±1.60 [mean colony forming unit (cfu) x 105±standard deviation (SD)] in group 1, 0.12±0.56 in group 2, 0.11±0.65 in group 3, and 0.01±0.001 in group 4. Significant difference was found between group 1 and all other groups (p<0.05), and between group 4 and all other groups (p<0.05). According to SEM analysis, counts of bacteria (mean±SD) were 1.88±0.45, 0.75±0.26, 0.21±0.22, and 0.13±0.25 in groups 1, 2, 3, and 4, respectively. Significant difference was found between group 1 and all other groups (p<0.05), and between group 4 and all other groups (p<0.05). CONCLUSION: N-acetyl cysteine, teicoplanin, and their combination significantly reduced formation of biofilm compared to the control group. Also, combination of NAC and teicoplanin had the highest antibiofilm effect.
[Mh] Termos MeSH primário: Acetilcisteína/farmacologia
Antibacterianos/farmacologia
Biofilmes/efeitos dos fármacos
Expectorantes/farmacologia
Staphylococcus aureus/efeitos dos fármacos
Teicoplanina/farmacologia
[Mh] Termos MeSH secundário: Carga Bacteriana
Cimentos para Ossos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bone Cements); 0 (Expectorants); 61036-62-2 (Teicoplanin); WYQ7N0BPYC (Acetylcysteine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170615
[Lr] Data última revisão:
170615
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE


  10 / 2246 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28231655
[Au] Autor:Xiao T; Chen XY; Wang N; Zhao Q; Fu CW; Xu B
[Ad] Endereço:School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai 200032, China.
[Ti] Título:[Study on the situation of drug use in patients with chronic obstructive pulmonary diseases in the Chinese communities of large cities].
[So] Source:Zhonghua Liu Xing Bing Xue Za Zhi;38(2):142-146, 2017 Feb 10.
[Is] ISSN:0254-6450
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To understand the medication being used among patients with chronic obstructive pulmonary diseases (COPD) in Chinese communities of large cities. A cross-sectional survey was carried out in Beijing, Shanghai, Chengdu and Guangzhou with the total number as 678 COPD cases who were continuously recruited. Subjects were face-to-face interviewed using a structured questionnaire and with medical records checked at the same time. All data were double entered into a database under EpiData 3.1, and analyzed by SAS 9.2. One quarter of all the subjects did not receive any clinical treatment. The top three drugs for COPD were expectorant (50.74%), phosphodiesterase inhibitors (49.56%), and leukotriene (49.12%). Totally, there were 36 different types combination of drugs used for COPD and the proportions of drugs being used as one, two, and three or more at the same time were 29.5%(200 cases), 39.7%(269 cases) and 30.8%(209 cases) respectively. In addition 36.6% (248 cases) of them used oxygen. There were statistical correlations between drug-use patterns and the severity of COPD. The patterns of medication varied over COPD cases in communities from Chinese large cities and appeared differently under the recommendations in the clinical guidelines set for COPD. Guidance and surveillance programs on drugs use for COPD should be improved on patients with COPD in the Chinese communities.
[Mh] Termos MeSH primário: Grupo com Ancestrais do Continente Asiático/estatística & dados numéricos
Expectorantes/uso terapêutico
Leucotrienos/uso terapêutico
Inibidores de Fosfodiesterase/uso terapêutico
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
China/epidemiologia
Cidades
Estudos Transversais
Feminino
Seres Humanos
Entrevistas como Assunto
Masculino
Meia-Idade
Aceitação pelo Paciente de Cuidados de Saúde/etnologia
Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos
Doença Pulmonar Obstrutiva Crônica/etnologia
Índice de Gravidade de Doença
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Expectorants); 0 (Leukotrienes); 0 (Phosphodiesterase Inhibitors)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170224
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0254-6450.2017.02.002



página 1 de 225 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde